Efficacy and Safety of Coadministered Irbesartan and Atorvastatin in Patients With Hypertension and Hyperlipidemia

NCT01442987 Phase 3 COMPLETED

The purpose of this study is to evaluate efficacy and safety of coadministered Irbesartan and Atorvastatin in patients with hypertension and hyperlipidemia.

Details

Lead sponsor	Hanmi Pharmaceutical Company Limited
Phase	Phase 3
Status	COMPLETED
Enrolment	230
Start date	2011-05
Completion	2013-05

Conditions

• Hypertension
• Hyperlipidemia

Interventions

• Irbesartan/Atorvastatin A
• Irbesartan
• Atorvastatin A
• Placebo
• Irbesartan/Atorvastatin B
• Atorvastatin B

Primary outcomes

• Percent change from baseline to 8 week in LDL-Cholesterol — baseline and 8 week
• Change from baseline to 8 week in Blood Pressure. — baseline and 8 week

Countries

South Korea